A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers. (NCT03505190), a randomized phase 1 study. The primary outcome is Percentage of Participants With Adverse Events and AEs of Special Interest.

2. Clinical Question

This is a safety and pharmacokinetic study rather than a trial designed to establish a clinical benefit. The primary endpoint describes the occurrence of adverse events in the safety population. Adverse events of special interest included elevated ALT or AST together with elevated bilirubin or clinical jaundice, suspected transmission of an infectious agent by the study drug, severe injection site reactions, and renal adverse events.

The registry record reports counts of participants with serious and other adverse events by group. It does not report numerical pharmacokinetic findings or inferential comparisons. Consequently, the posted information allows a descriptive account of the event counts, but it does not establish whether the dose groups differed statistically or how the pharmacokinetic measures changed across dose levels.

3. Trial Design

This was a Phase 1, randomized, placebo-controlled, single-ascending-dose study in healthy Chinese volunteers. The intervention was RO7062931 administered subcutaneously, with dose groups of 0.3mg/kg, 1.0mg/kg, 2.0mg/kg, and 4.0mg/kg, alongside a matching-placebo group. The registry record describes the model as sequential. It does not report the detailed rules used to move between dose levels, so the precise dose-escalation procedure cannot be characterized from the record.

The masking description is sponsor-open, investigator-blind, and subject-blind; the record also classifies masking as double. These descriptions indicate that the sponsor was not blinded while investigators and participants were. The specific procedures used to maintain masking, and whether anyone else had access to treatment assignments, are not reported in the registry record. The record does not provide the randomization method or allocation ratio.

The registry reports an enrollment of 41 and a primary completion date of 2019-07-05. Study start is listed as 2018-05-03, and the study status is completed. The primary safety outcome was assessed up to 16 weeks. The safety population was defined as healthy volunteers who received at least one dose of study medication, including participants who withdrew prematurely.

The stated objectives were safety, tolerability, and pharmacokinetics following single ascending subcutaneous doses. Listed pharmacokinetic outcomes include maximum plasma concentration, time to maximum concentration, area under the concentration-time curve, terminal elimination half-life, apparent clearance, apparent volume of distribution, and cumulative urinary excretion. Numerical results for these outcomes are not reported in the registry record. The record does not report a sample-size justification or the detailed statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: The Safety Population was defined as all Healthy Volunteers who have received at least one dose of the study medication, whether prematurely withdrawn from the study or not.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Adverse Events and AEs of Special Interest, measured over Up to 16 weeks.

The primary endpoint is the percentage of participants with adverse events and adverse events of special interest, assessed up to 16 weeks. It applies to the Safety Population: healthy volunteers who received at least one dose of study medication, whether or not they subsequently withdrew. The registry record includes event counts by treatment group, but the numerical endpoint percentages and uncertainty estimates are not reported in the registry record.

The special-interest events were defined as elevated ALT or AST together with elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by the study drug; severe injection site reactions; and renal adverse events. These categories identify events of particular interest for monitoring in this study. Their definition does not mean that any such event occurred.

In general, a safety endpoint based on the proportion of participants with an event is useful for describing how many participants experienced events during the specified observation period. It is a descriptive measure: by itself, it does not show that an event was caused by treatment or that event frequencies differ reliably between groups. Interpretation also depends on how events were collected, how participants were followed, and how missing observations were handled; these details are not reported in the registry record.

The primary endpoint concerns safety, while the listed secondary outcomes concern pharmacokinetics. The registry record does not report numerical pharmacokinetic findings. The event counts therefore cannot answer the pharmacokinetic questions or provide a complete account of all stated study objectives.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count describe?

The adverse-event summaries report how many participants in each group were at risk and how many were recorded as affected. In general, a count is a direct description of observed participants, while a percentage expresses that count relative to a defined denominator. The primary endpoint is defined as a percentage, but the registry record reports group counts rather than numerical endpoint percentages. No percentages should be inferred from those counts without a separately stated calculation.

Counts are often easier to interpret when the denominator and observation period are clear. Here, the registry defines the Safety Population as participants who received at least one dose and specifies an outcome timeframe up to 16 weeks. The record does not provide further details about the duration of observation for each participant or how incomplete follow-up was treated. Those details matter because participants with different follow-up durations may have different opportunities for an event to be recorded.

What can a randomized comparison establish?

In general, randomization is intended to reduce systematic differences between groups at the time of assignment. It does not guarantee that groups are identical, particularly in a study with modest group sizes, and it does not eliminate uncertainty in observed event counts. A placebo group provides a concurrent comparison, but a valid interpretation still depends on how allocation was carried out, whether follow-up was comparable, and whether outcomes were assessed consistently. The registry record does not report the randomization procedure or allocation ratio.

The study was described as sponsor-open, investigator-blind, and subject-blind, and also classified as double-masked. In general, blinding can reduce the chance that knowledge of treatment assignment influences participant reporting or investigator assessment. The registry record does not explain the masking procedures or describe whether the blind was maintained throughout follow-up. This limits assessment of how masking was implemented.

Why is a confidence interval useful?

In general, a confidence interval gives a range of values compatible with the observed data under a specified statistical procedure. It communicates precision as well as the direction and scale of an estimate. A count by itself does not show how uncertain a comparison is. The registry record does not report confidence intervals for the primary endpoint, so the precision of differences between groups cannot be assessed from the posted results.

Similarly, a hypothesis test evaluates data against a stated null hypothesis under defined assumptions. A p-value, when reported, is not a measure of the probability that a treatment works, nor does it convey the size or practical importance of an effect. The registry record lists no analyses and reports no p-values for the primary endpoint. It is therefore not possible to describe a formal statistical comparison from the record.

How should the sequential design be understood?

The registry describes the study model as sequential and the dose approach as single ascending dose. In general, sequential dose studies evaluate dose groups in an ordered process, but the exact decision rules can vary. The registry record does not report the rules for escalation, pausing, or stopping. No assumptions about those rules should be made from the design label alone.

Because the study examines several dose groups and a placebo group, there are multiple possible pairwise or trend comparisons. In general, making many statistical comparisons can increase the chance of at least one false-positive result if multiplicity is not addressed. The registry record does not report a multiplicity adjustment or an analysis plan specifying which comparisons were intended. Since no inferential analyses are listed, there are no reported comparative tests to interpret.

What do the sample-size illustrations mean?

In general, a sample-size calculation uses assumptions about a target effect, variability or event frequency, significance level, power, and allocation to estimate the number of participants needed for a planned analysis. A planning illustration based on an observed effect is not evidence that a study had a particular probability of finding a result. It is not observed power. The registry record describes planning illustrations as hypothetical calculations using a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the detectable effect expressed as a fraction of the observed effect. These assumptions describe planning illustrations, not the trial's own design justification. A sample-size justification is not reported in the registry record.

The record does not report the estimates or comparisons needed to interpret a numerical planning illustration for this primary outcome. The event endpoint is presented as counts, and no formal primary analysis is listed. Consequently, no conclusion about the study's statistical power or ability to detect a specified difference can be drawn from the record.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 14 outcome measures and 0 analyses. It identifies a primary safety endpoint and several secondary pharmacokinetic outcomes, but does not report a detailed analysis plan, planned contrasts, or a procedure for handling multiple comparisons. In general, when multiple outcomes or comparisons are tested, multiplicity can increase the chance of a false-positive result unless the analysis plan addresses it. No multiplicity adjustment is reported in the registry record. Because no inferential analyses are listed, there are no reported adjusted or unadjusted tests to compare.

The record does not describe missing-data handling, the amount of missing outcome data, or whether participants with incomplete follow-up were included in each analysis. It does define the Safety Population as healthy volunteers who received at least one dose, including those who withdrew prematurely. That definition describes who can enter the safety population; it does not explain how missing observations after withdrawal were handled.

The registry record does not report an intention-to-treat population or another analysis population for the pharmacokinetic outcomes. Nor does it report an interim analysis or stopping rule. These omissions do not demonstrate that such methods were absent from the full study documentation; they mean only that the registry record does not report them. The absence of listed analyses also prevents assessment of whether prespecified methods were followed or whether analyses changed after data collection.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The serious adverse-event summaries report 0 affected participants in each RO7062931 dose group and 0 in the placebo group. The corresponding numbers at risk are 9, 8, 8, 8, and 8. No deaths are reported. These are observed counts in the posted safety summaries, not proof that serious events could not occur or that the groups have identical risks.

For other adverse events, the reported numbers of affected participants are 6, 5, 5, and 6 across the ascending RO7062931 dose groups, and 7 in the placebo group. The record does not provide event-level detail, severity categories for these other events, or attribution to the study medication. It also does not separately report the counts for each adverse event of special interest.

In general, a zero count means that no event was recorded in the observed participants during the recorded follow-up; it does not establish a zero underlying risk. Counts also depend on the number of participants observed and the event-collection procedures. The registry record does not report confidence intervals or a formal comparison, so the precision of differences between groups cannot be assessed from these summaries.

12. What the Result Does, and Does Not, Mean

The registry record describes a randomized Phase 1 study of single ascending subcutaneous doses of RO7062931 and matching placebo in healthy Chinese volunteers. Its posted safety results report no serious adverse events and no deaths in any group, alongside counts of participants with other adverse events. These are descriptive observations from the participants included in the safety summaries.

The findings do not establish that the treatment caused or prevented any event. They also do not show that the event experience was statistically different between dose groups or compared with placebo: the registry record reports no formal analyses, p-values, or confidence intervals for the primary endpoint. Counts alone cannot determine the size or precision of a between-group difference.

The record lists pharmacokinetic outcomes, including maximum concentration, time to maximum concentration, area under the concentration-time curve, terminal elimination half-life, apparent clearance, apparent volume of distribution, and urinary excretion. Numerical results for those outcomes are not reported in the registry record. The posted safety summaries therefore cannot answer whether exposure or other pharmacokinetic measures varied across dose groups.

This study's healthy-volunteer setting and single-dose design define the context of the observations. The registry record does not report results in patients or outcomes of clinical benefit. The data should be read as a limited account of recorded adverse-event counts and not as a comprehensive assessment of longer-term safety, comparative safety, or clinical effectiveness.

13. Why This Trial Matters Statistically

Early-phase studies can be statistically informative even when their purpose is not to test clinical benefit. A structured dose study can collect safety and pharmacokinetic information across planned dose groups. In general, describing the design, endpoint, population, and uncertainty helps readers distinguish an exploratory safety account from a confirmatory comparison.

This study's registry record specifies a safety endpoint, defines the safety population, and identifies the follow-up timeframe. Those details help establish what the endpoint is intended to describe. The record also lists pharmacokinetic outcomes, making clear that the study's objectives extended beyond adverse events. However, numerical pharmacokinetic results and inferential analyses are not reported, so the statistical account available from the registry is incomplete for those objectives.

The adverse-event counts illustrate why denominators and uncertainty matter. The groups have limited numbers of participants, and simple counts do not show the precision of event-frequency estimates. In general, absence of recorded serious events in a study does not establish absence of risk; it describes what was observed in that study under its follow-up and event-collection procedures. Comparisons also require a defined analysis and appropriate uncertainty estimates.

For clinical researchers and biostatisticians, the distinction between observed results and statistical inference is central. A registry record can identify the planned endpoint and disclose observed counts, but without analysis details it cannot resolve questions about between-group differences, missing outcomes, multiplicity, or robustness. This study therefore provides a useful example of how much interpretation depends on transparent reporting of both design and analysis.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report numerical results for the listed pharmacokinetic outcomes. This prevents assessment of concentration profiles, exposure, or other pharmacokinetic patterns across dose groups. Although the primary outcome is defined as a percentage, the posted summaries contain event counts rather than numerical endpoint percentages or uncertainty estimates.

No inferential analyses are listed. The record therefore does not provide formal comparisons, confidence intervals, or p-values for the primary safety endpoint. It does not report an analysis plan, a sample-size justification, or the details needed to assess planned comparisons and multiplicity. The sample-size assumptions described for planning illustrations do not establish that the trial was designed around those assumptions.

Information about missing data and follow-up completeness is not reported in the registry record. The safety population definition includes participants who received at least one dose, including those who withdrew prematurely, but the record does not explain how observations after withdrawal were handled. It also does not provide event-level descriptions, timing, attribution, or separate counts for each adverse event of special interest.

The sequential model is stated, but dose-escalation decision rules are not reported. The registry record also does not describe the randomization procedure, allocation ratio, or detailed masking procedures. These limitations restrict evaluation of the study's operational methods and the precision and comparability of its safety summaries. The findings should be interpreted within the scope of the reported participant groups, single-dose design, and available descriptive results.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers. — NCT03505190.
• Registry record last updated 2020-08-03; status last verified 2020-07.
• Results first posted 2020-08-03.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03505190 is a completed Phase 1 randomized, placebo-controlled, single-ascending-dose study of subcutaneous RO7062931 in healthy Chinese volunteers. The registry reports enrollment of 41 and a safety follow-up timeframe up to 16 weeks. The dose groups were 0.3mg/kg, 1.0mg/kg, 2.0mg/kg, and 4.0mg/kg, with a matching-placebo group.

The primary endpoint was the percentage of participants with adverse events and adverse events of special interest. The posted safety counts report no serious adverse events and no deaths in any group, and report participants with other adverse events in each group. Numerical pharmacokinetic results, formal analyses, and uncertainty estimates are not reported in the registry record.